Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the launch ...
The global mesotherapy market, valued at US$ 801.2 Mn in 2023, is set to experience steady growth over the next decade. With ...
"The global industry was valued at US$ 37.0 Bn in 2023 and is projected to reach US$ 64.8 Bn by 2034, growing at a CAGR of ...
UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...
Xcell Biosciences Australia PTY LTD (Xcellbio), an affiliate of Xcell Biosciences, Inc., a platform company focused on cell and gene therapy applications, and Royal Perth Hospital announced a ...
Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, and an Operating Company of Danaher Corporation (NYSE: DHR), revolutionizes spectral flow cytometry with the ...
Senzime AB today announced that it has secured new important US hospital system contracts including initial delivery of 60 next-generation TetraGraph neuromuscular monitoring systems to an Integrated ...
Water treatment solutions specialist Arvia Technology has announced the launch of Florenox™, a range of electrochemical oxidation reactors that can destroy per- and polyfluoroalkyl substances (PFAS) ...
Ondine Biomedical, a global leader in light-activated antimicrobial technologies, is pleased to announce that patient recruitment has commenced in an intensive care unit (ICU) pilot study at Royal ...
Research Institute to advance nutraceutical product development across four core research areas17/03/25, SIRIO Pharma (SIRIO) – the global nutraceutical contract development and manufacturing ...
March-2025 / 06:59 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.PRESS RELEASERelease of an ad hoc announcement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results